- Home
- ZYXI vs CLLS Comparison
ZYXI vs CLLS Comparison
Compare ZYXI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYXI
- CLLS
- Stock Information
- Founded
- ZYXI 1996
- CLLS 1999
- Country
- ZYXI United States
- CLLS France
- Employees
- ZYXI N/A
- CLLS N/A
- Industry
- ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- ZYXI Health Care
- CLLS Health Care
- Exchange
- ZYXI Nasdaq
- CLLS Nasdaq
- Market Cap
- ZYXI 72.3M
- CLLS 143.4M
- IPO Year
- ZYXI N/A
- CLLS 2007
- Fundamental
- Price
- ZYXI $2.46
- CLLS $1.61
- Analyst Decision
- ZYXI Buy
- CLLS Buy
- Analyst Count
- ZYXI 3
- CLLS 1
- Target Price
- ZYXI $6.00
- CLLS $4.00
- AVG Volume (30 Days)
- ZYXI 255.9K
- CLLS 52.1K
- Earning Date
- ZYXI 07-24-2025
- CLLS 08-05-2025
- Dividend Yield
- ZYXI N/A
- CLLS N/A
- EPS Growth
- ZYXI N/A
- CLLS N/A
- EPS
- ZYXI N/A
- CLLS N/A
- Revenue
- ZYXI $172,401,000.00
- CLLS $54,747,000.00
- Revenue This Year
- ZYXI N/A
- CLLS $48.52
- Revenue Next Year
- ZYXI $19.55
- CLLS $5.17
- P/E Ratio
- ZYXI N/A
- CLLS N/A
- Revenue Growth
- ZYXI N/A
- CLLS 351.26
- 52 Week Low
- ZYXI $1.66
- CLLS $1.10
- 52 Week High
- ZYXI $10.62
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- ZYXI 51.32
- CLLS 61.29
- Support Level
- ZYXI $2.31
- CLLS $1.56
- Resistance Level
- ZYXI $2.72
- CLLS $1.49
- Average True Range (ATR)
- ZYXI 0.18
- CLLS 0.09
- MACD
- ZYXI -0.00
- CLLS 0.02
- Stochastic Oscillator
- ZYXI 29.81
- CLLS 86.67
About ZYXI Zynex Inc.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.